DM1-SMe is widely utilized in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. Its potent cytotoxic properties make it an effective payload that can be attached to monoclonal antibodies, enabling precise delivery to cancer cells while minimizing damage to healthy tissues. This compound is particularly valuable in treating various cancers, including breast cancer, lymphoma, and leukemia, where it disrupts microtubule function, leading to cell cycle arrest and apoptosis. Its application in ADCs represents a significant advancement in personalized medicine, offering improved therapeutic outcomes and reduced side effects compared to traditional chemotherapy.